leadf
logo-loader
viewMindMed

MindMed investigating potential benefits of DMT in upcoming Phase 1 clinical trial collaboration

Mind Medicine Inc (NEO:MMED) (OTCQB:MMEDF) CEO JR Rahn tells Proactive it is pursuing research into DMT, the active ingredient in Ayahuasca.

Rahn says its part of a research and development collaboration that the psychedelics company has with the University Hospital Basel’s Liechti Lab. MindMed will provide startup funding for a Phase 1 clinical trial looking at intravenous dosing regimen options for DMT.

Quick facts: MindMed

Price: 1.89 USD

OTCQB:MMEDF
Market: OTCQB
Market Cap: $616.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MindMed named herein, including the promotion by the Company of MindMed in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

MindMed Inc. looks to up-list to the Nasdaq amidst rise in popularity of...

Mind Medicine (MindMed) Inc (NEO:MMED)(OTCQB:MMEDF) CEO JR Rahn the leading drug development company for psychedelic-inspired medicines tells Proactive the group is evaluating an expanded US investor base through an up-listing on the Nasdaq Capital Market. What's more, Rahn says MindMed is...

on 10/07/2020

2 min read